{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:32:39Z","timestamp":1779114759992,"version":"3.51.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020618","name":"Institut de Recerca contra la Leuc\u00e8mia Josep Carreras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The aim of this study was to describe incidence, incidence trends and survival patterns of lymphoid neoplasms (LNs) and its subtypes in Spain in the period 2002-2013 using data from the Spanish Network of Cancer Registries (REDECAN).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Data were extracted from 13 Spanish population-based cancer registries. LNs incident cases were codified using the International Classification of Diseases for Oncology, third edition (ICD-O-3) and grouped according to the WHO 2008 classification. Age-standardized incidence rates to the 2013 European standard population (ASIRe) were obtained. Poisson regression models were used to analyze trends in incidence rates and estimate the annual percentage change (APC) for each subtype. The number of cases in Spain for 2023 was estimated by applying the estimated age-specific rates for the year 2023 to the 2023 Spanish population. Observed survival (OS) was estimated by the Kaplan-Meier method and net survival (NS) by the Pohar-Perme method. Sex- and age-specific estimates of 5-year NS were calculated, as well as its changes according to two periods of diagnosis (2002-2007 and 2008-2013).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>LNs accounted for 69% (n=39,156) of all hematological malignancies (n=56,751) diagnosed during the period of study. Median age at diagnosis was 67 years (interquartile range (IQR) = 52-77). The overall ASIRe was 34.23 (95% confidence interval (CI): 33.89, 34.57) and showed a marked male predominance in almost all subtypes (global sex ratio = 1.45). During the study period, incidence trends of LNs remained stable (APC: 0.3; 95% CI: -0.1, 0.6), nevertheless some subtypes showed statistically significant variations, such as LNs NOS category (APC: -5.6; 95% CI: -6.8, -4.3). Around 17,926 new cases of LNs will be diagnosed in 2023 in Spain. Survival rates differed considerably across age-groups, while they were similar between men and women. Five- year NS was 62.81% (95% CI: 62.1, 63.52) for all LNs, and varied widely across LNs subtypes, ranging from 39.21% to 90.25%. NS for all LNs improved from the first period of diagnosis to the second one, being 61.57% (95% CI: 60.56, 62.61) in 2002-2007 and 64.17% (95% CI: 63.29, 65.07) in 2008-2013.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study presents the first complete and extensive population-based analysis of LNs incidence and survival in Spain. These population-based data provide relevant information to better understand the epidemiology of LNs in Southern Europe and it features some useful points for public health authorities and clinicians. However, additional improvements regarding the registration of these hematological neoplasms can be implemented.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1046307","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T09:43:25Z","timestamp":1669628605000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Incidence and survival of lymphoid neoplasms in Spain, 2002-2013: A population-based study from the Spanish Network of Cancer Registries (REDECAN)"],"prefix":"10.3389","volume":"12","author":[{"given":"Cl\u00e0udia","family":"Pla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Solans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ameijide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantza","family":"Sanvisens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00e0","family":"Carulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Araceli","family":"Alem\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"S\u00e1ez-Lloret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"D\u00edaz-del-Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Isabel","family":"Marcos-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leire","family":"Sainz-de-Aja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaia","family":"Aizpurua-Atxega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantza","family":"Lopez-de-Munain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Jos\u00e9","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefina","family":"Perucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Franch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Dolores","family":"Chirlaque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Galceran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Marcos-Gragera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"REDECAN working group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-077982","article-title":"Classification of lymphoid neoplasms: the microscope as a tool for disease discovery","volume":"112","author":"Jaffe","year":"2008","journal-title":"Blood"},{"key":"B3","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"B4","author":"Swerdlow","year":""},{"key":"B5","article-title":"Classification of tumours of haematopoietic and lymphoid tissues","volume-title":"World health organization classification of tumours","author":"Swerdlow","year":"2016"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/S41375-022-01625-X","article-title":"The WHO classification of haematolymphoid tumours","volume":"36","author":"Cree","year":"2022","journal-title":"Leukemia"},{"key":"B7","article-title":"International classification of diseases for oncology, third edition","author":"Fritz","year":"2000","journal-title":"World Health Organ"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's haematological malignancy research network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.956315","article-title":"The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry","volume":"56","author":"Dandoit","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.034264","article-title":"Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: Results of the HAEMACARE project","volume":"96","author":"Marcos-Gragera","year":"2011","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.08.003","article-title":"Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study","volume":"51","author":"De Angelis","year":"2015","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the united states, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canep.2018.11.001","article-title":"Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the girona province, Spain","volume":"58","author":"Solans","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canep.2020.101841","article-title":"Population-based survival of lymphoid neoplasms: Twenty years of epidemiological data in the girona province, Spain","volume":"69","author":"Villavicencio","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"B17","unstructured":""},{"key":"B18","unstructured":""},{"key":"B19","volume-title":"Standards and guidelines for cancer registration in Europe: the ENCR recommendations","author":"Tyczynski","year":"2003"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2011.01640.x","article-title":"On estimation in relative survival","volume":"68","author":"Perme","year":"2012","journal-title":"Biometrics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12874-017-0351-3","article-title":"On comparison of net survival curves","volume":"17","author":"Pavli\u010d","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28849","article-title":"Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006","volume":"135","author":"van Leeuwen","year":"2014","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/jncimonographs\/lgu007","article-title":"Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: The interlymph non-hodgkin lymphoma subtypes project","volume":"48","author":"Smedby","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061748","article-title":"Prescription of blood lymphocyte immunophenotyping in the diagnosis of lymphoid neoplasms in older adults","volume":"11","author":"Vovelle","year":"2022","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ejca.2006.10.008","article-title":"Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe","volume":"43","author":"Adamson","year":"2007","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0549","article-title":"Changes in cancer registry coding for lymphoma subtypes: Reliability over time and relevance for surveillance and study","volume":"15","author":"Clarke","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28690","article-title":"Incidence of chronic lymphocytic leukemia and high-count monoclonal b-cell lymphocytosis using the 2008 guidelines","volume":"120","author":"Call","year":"2014","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"US Lymphoid malignancy statistics by world health organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27830","article-title":"Cancer net survival on registry data: Use of the new unbiased pohar-perme estimator and magnitude of the bias with the classical methods","volume":"132","author":"Roche","year":"2013","journal-title":"Int J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102441","article-title":"Cancer survival in adults in Spain: A population-based study of the Spanish network of cancer registries (REDECAN)","volume":"14","author":"Guevara","year":"2022","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00241-6","article-title":"A comprehensive approach to therapy of haematological malignancies in older patients","volume":"8","author":"Cordoba","year":"2021","journal-title":"Lancet Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.245803","article-title":"Geriatric assessment in older patients with a hematologic malignancy: A systematic review","volume":"105","author":"Scheepers","year":"2020","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1461","article-title":"Incidence and survival of hematological cancers among adults ages \u226575 years","volume":"7","author":"Krok-Schoen","year":"2018","journal-title":"Cancer Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0724-7","article-title":"Sexual dimorphism in solid and hematological malignancies","volume":"41","author":"Ben-Batalla","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41568-021-00348-y","article-title":"Sex disparities matter in cancer development and therapy","volume":"21","author":"Haupt","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.5878","article-title":"Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies","volume":"29","author":"Moreau","year":"2011","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15170","article-title":"Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's haematological malignancy research network (HMRN)","volume":"181","author":"Smith","year":"2018","journal-title":"Br J Haematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008-2015. real-world data on 4904 patients from the Swedish myeloma registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02541-1","article-title":"Trends of incidence, mortality and survival of multiple myeloma in spain. a twenty-three-year population-based study","volume":"23","author":"Chang-Chan","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/J.MEDCLI.2021.09.035","article-title":"En representaci\u00f3n de la red espa\u00f1ola de registros de c\u00e1ncer (REDECAN). estimates of the incidence of hematological neoplasms in Spain, 2021","volume":"158","author":"Sanvisens","year":"2022","journal-title":"Med Clin (Barc)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2020.04.011","article-title":"Implicaciones de la pandemia por COVID-19 sobre el c\u00e1ncer en espa\u00f1a [Implications of the COVID-19 pandemic for cancer in Spain]","volume":"155","author":"Petrova","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30388-0","article-title":"The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study","volume":"21","author":"Maringe","year":"2020","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27889","article-title":"Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France","volume":"132","author":"Monnereau","year":"2013","journal-title":"Int J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1046307\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T09:43:29Z","timestamp":1669628609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1046307\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":45,"alternative-id":["10.3389\/fonc.2022.1046307"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1046307","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"article-number":"1046307"}}